Showing results (31-40 of 112) with videos related to
Sort By:
Pageof 12
Investigational New Drugs|July 18, 2016
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumorsLee S Rosen, Patricia LoRusso, Wen Wee Ma, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2022
ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyMelissa Johnson, Arkadiusz Z Dudek, Ammar Sukari, et al.Biomicrofluidics|December 24, 2015
High efficiency vortex trapping of circulating tumor cellsManjima Dhar, Jessica Wong, Armin Karimi, et al.Investigational New Drugs|December 3, 2017
Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancerJonathan W Goldman, Lee S Rosen, Anthony W Tolcher, et al.JAMA Oncology|January 11, 2024
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled TrialTrudy C Wu, Elaine Luterstein, Beth K Neilsen, et al.Journal of Hematology & Oncology|March 23, 2017
A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemiaSaroj Vadhan-Raj, Rafat Abonour, Jonathan W Goldman, et al.Clinical Lung Cancer|April 11, 2022
A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to ErlotinibD Ross Camidge, Teresa Moran, Ingel Demedts, et al.JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2025
First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast CancerTimothy A Yap, Jonathan W Goldman, Shaveta Vinayak, et al.Clinical and Translational Science|December 19, 2020
Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small-Cell Lung CancerJonathan W Goldman, Minal Barve, Jyoti D Patel, et al.Pageof 12